Directed evolution of hydroxylases for aromatic metabolism
Innovative biocatalysts engineered through directed evolution to enhance mono-hydroxylation of diverse aromatic substrates, offering potential applications in bioremediation and synthesis.
Overview
The directed evolution of hydroxylases offers a groundbreaking approach to enhance the mono-hydroxylation of a wide variety of aromatic compounds. These biocatalysts, engineered to broaden their substrate range, are pivotal in destabilizing aromatic rings, making them invaluable for applications in bioremediation and the synthesis of fine chemicals. By leveraging the natural capabilities of microorganisms to metabolize aromatic molecules, this technology aims to optimize enzyme performance for industrial applications.
Technical specifications
Key features:
- Engineered hydroxylases capable of mono-hydroxylation of a diverse array of aromatic substrates
- Utilizes directed and random mutagenesis to evolve enzyme variants with improved activity and selectivity
- Enzyme activity monitored through co-substrate consumption and product formation using advanced analytical techniques like HPLC-MS
- Scaled-up expression in recombinant hosts such as Escherichia coli and Pseudomonas putida for industrial applications
Technology readiness level
Currently, this technology is at TRL 3, indicating that active research and development are underway with experimental proof of concept demonstrated. Future plans include further optimization and scaling up of the best performing enzymes to validate their efficacy in larger-scale processes.
About Imperial College London
Imperial College London is a STEM‑focused public research university with a large postgraduate community and an entrepreneurial culture. Industry engages through the White City innovation district, where the university offers incubator and scale‑up labs, wet‑lab and prototyping facilities, co‑location with corporate R&D and startups, and a dedicated technology transfer office. Integration with a major NHS hospital system provides access to clinical cohorts, trials infrastructure, and translational expertise, while corporate relations streamline sponsored research and consortia. Research is supported by competitive funding from UK Research and Innovation councils, the National Institute for Health and Care Research, European programs, and major foundations.
delivered to your inbox.